a

a - a

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008484

Enrollment

Registered

2012-07-20

Start date

2012-07-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial cystitis/ Hypersensitive bladder syndrome

Interventions

Administration of mirabegron 50mg per day for four weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with IC/ HSB whose diagnose confirmed at our institution. 2. Patients 3. Patiens score VAS 3 points or more, and urinate 12times or more per day. 4. Patients who can be treated at outpatient clinic.

Exclusion criteria

Exclusion criteria: a

Design outcomes

Primary

Measure	Time frame
Average voided volume at four weeks of the drug administration.	—

Countries

Japan

Contacts

Public ContactAkira Nomiya

University of Tokyo Department of Urology, Graduate school of medicine

03-5800-8753

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

a